Related references
Note: Only part of the references are listed.Achieving clinical success with BET inhibitors as anti-cancer agents
Tatiana Shorstova et al.
BRITISH JOURNAL OF CANCER (2021)
The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment
Ekaterina Kim et al.
LEUKEMIA (2020)
Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation
Omer Gilan et al.
SCIENCE (2020)
Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer
Pravien Rajaram et al.
MOLECULES (2020)
The BET inhibitor CPI203 promotes ex vivo expansion of cord blood long-term repopulating HSCs and megakaryocytes
Peng Hua et al.
BLOOD (2020)
The emerging role of BET inhibitors in breast cancer
Angeliki Andrikopoulou et al.
BREAST (2020)
Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer
Daisuke Obinata et al.
FRONTIERS IN ONCOLOGY (2020)
Integrated pharmacokinetic (PK)/pharmacodynamic (PD) modeling leveraging PK, biomarker, and safety data to support dose and schedule selection for the BET inhibitor BMS-986158
Xi (Cindy) Chen et al.
CANCER RESEARCH (2020)
Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors
Sarina A. Piha-Paul et al.
JNCI CANCER SPECTRUM (2020)
Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor
David Sperandio et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2019)
First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity
Sophie Postel-Vinay et al.
EUROPEAN JOURNAL OF CANCER (2019)
The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer
Yuqian Yan et al.
EMBO MOLECULAR MEDICINE (2019)
Phase 1 Dose Escalation and Expansion Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BET Inhibitor FT-1101 As a Single Agent in Patients with Relapsed or Refractory Hematologic Malignancies
Manish R. Patel et al.
BLOOD (2019)
Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases
Jose Luis Morgado-Pascual et al.
FRONTIERS IN PHARMACOLOGY (2019)
Metabolic changes in patients with prostate cancer during androgen deprivation therapy
Koji Mitsuzuka et al.
INTERNATIONAL JOURNAL OF UROLOGY (2018)
BET Proteins as Targets for Anticancer Treatment
Anastasios Stathis et al.
CANCER DISCOVERY (2018)
Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer
Elena Bonazzoli et al.
CLINICAL CANCER RESEARCH (2018)
Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)
Jonathan Welti et al.
CLINICAL CANCER RESEARCH (2018)
Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma
Ileabett M. Echevarria-Vargas et al.
EMBO MOLECULAR MEDICINE (2018)
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors
Jeremy Lewin et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Maha Hussain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling
Amanda Balboni Iniguez et al.
CANCER CELL (2018)
HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues
Xiaoyu Lin et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
N. D. James et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors
Tammie C. Yeh et al.
CLINICAL CANCER RESEARCH (2017)
Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence
Isabel Coutinho et al.
ENDOCRINE-RELATED CANCER (2016)
BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer
Irfan A. Asangani et al.
MOLECULAR CANCER RESEARCH (2016)
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Kanak Raina et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
Celine Berthon et al.
LANCET HAEMATOLOGY (2016)
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J. Ryan et al.
LANCET ONCOLOGY (2015)
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
Irfan A. Asangani et al.
NATURE (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Cell-Autonomous Intracellular Androgen Receptor Signaling Drives the Growth of Human Prostate Cancer Initiating Cells
Donald J. Vander Griend et al.
PROSTATE (2010)
Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
Rong Hu et al.
CANCER RESEARCH (2009)
Molecular determinants of resistance to antiandrogen therapy
CD Chen et al.
NATURE MEDICINE (2004)
Share Paper
